TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05008224
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age).
Study: NCT05008224
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study: NCT00124098
Drug: Aranesp® (darbepoetin alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05464784
Drug: MN-001
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-001 is a novel, orally bioavailable small molecule compound
Study: NCT05464784
Drug: MN-001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
Study: NCT06382142
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration for a cycle of 3 weeks.
Study: NCT06379893
Drug: Voltaren Gel 1% (diclofenac sodium) (US only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
Study: NCT06379893
Drug: Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
Study: NCT06379893
Drug: Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
Study: NCT05736367
Drug: U-13C-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
Study: NCT06285916
Drug: NORA520 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NORA520 tablets Dose 1 for 3 days
Study: NCT06285916
Drug: NORA520 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NORA520 tablets Dose 2 for 3 days
Study: NCT06285916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablets for 3 days
Study: NCT06107725
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
Study: NCT05965414
Drug: CS6253 Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
Study: NCT05965414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution for intra-venous injection
Study: NCT05655013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline 100 mL
Study: NCT05324982
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally self-administered by study participants.
Study: NCT05378503
Drug: Qsymia 3.75Mg-23Mg Extended Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: From W0 to W2, once a daily.
Study: NCT05378503
Drug: Qsymia 7.5Mg-46Mg Extended Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.
Study: NCT05378503
Drug: Qsymia 11.25Mg-69Mg Extended Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
Study: NCT05378503
Drug: Qsymia 15Mg-92Mg Extended Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
Study: NCT05378503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: From W0(Randomisation) to W56(the End of visit) once a daily.
Study: NCT06613659
Drug: traditional Chinese medicine (TCM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
Study: NCT06613659
Drug: non traditional Chinese medicine (non-TCM)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
Study: NCT06696859
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial culture (sputum ,blood and pleural fluid) Antibiotics sensitivity tests
Study: NCT06696586
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.
Study: NCT06696586
Drug: Fentanyl Injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
Study: NCT06319456
Drug: Cyclophosphamide，CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study: NCT05300269
Drug: SHR-1701；Capecitabine；Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w
Study: NCT00507364
Drug: Local injection of activated macrophages to anal fissure
Normalized name: eptacog alfa activated Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06031363
Drug: Indomethacin Suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
Study: NCT05569720
Drug: ApTOLL
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection.
Study: NCT06099535
Drug: LNK01001 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT06099535
Drug: LNK01001 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT06099535
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT06383520
Drug: 68Ga-aGPC3-scFv/Fab
Approvals — FDA: no, EMA: no, PMDA: no
Description: For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis.
Study: NCT05110664
Drug: Placibo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo solution
Study: NCT04832425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT05259917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to KVD900 Tablet
Study: NCT05259917
Drug: KVD900 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Study: NCT05259917
Drug: KVD900 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study: NCT04947423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study: NCT05731310
Drug: Angong Niuhuang Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
Study: NCT05283434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill placebo
Study: NCT04759664
Drug: LUT014 Gel (Dose 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT04759664
Drug: LUT014 Gel (Dose 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT04759664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUT014 matching placebo topical gel
Study: NCT05802888
Drug: Tetracycline 500mg tid
Normalized name: tetracycline hydrochloride 500 MG
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
Study: NCT05802888
Drug: Tetracycline 500mg qid
Normalized name: tetracycline hydrochloride 500 MG
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
Study: NCT05126316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Study: NCT06189586
Drug: intravenous injection of glucocorticoids
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
Study: NCT05725200
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study: NCT04737174
Drug: ES-481
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
Study: NCT05725200
Drug: Petrozumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study: NCT05284097
Drug: Ad26.ZEBOV, MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus
Study: NCT04570085
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
Study: NCT04570085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
Study: NCT05650502
Drug: saisonal malaria chimoprevention
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
Study: NCT05123716
Drug: placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT06176339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
Study: NCT06203769
Drug: 14-day antibiotic therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The studied intervention will be 14-day antibiotic therapy after removal of infected material
Study: NCT06203769
Drug: 28-day antibiotic therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The comparator arm will be 28-day antibiotic therapy after removal of infected material
Study: NCT05765032
Drug: SHR-A1921；
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
Study: NCT06308978
Drug: FT819
Normalized name: Furmonertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT819 will be administered as a single-dose intravenous (IV) infusion at planned dose levels.
Study: NCT06308978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Study: NCT05360732
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
Study: NCT05305911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for six months
Study: NCT05183555
Drug: 68Ga-DOTATOC PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
Study: NCT06475235
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
Study: NCT05211284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
Study: NCT05923996
Drug: microbotox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be treated by single session of microbotox injection
Study: NCT05374278
Drug: [18F]RP-115 PET/MRI or PET/CT and MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
Study: NCT05709015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
Study: NCT05211830
Drug: SXR1096 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study: NCT05211830
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study: NCT05739916
Drug: DA-1229_01 5/1000mg (Before)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05739916
Drug: DA-1229_01 5/1000mg (After)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT04699539
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
Study: NCT06042010
Drug: Oral zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
Study: NCT04634656
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
Study: NCT05786833
Drug: Dexmedetomedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
Study: NCT04815967
Drug: Phase 2; Low Dose MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04815967
Drug: Phase 2; High Dose MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04815967
Drug: Phase 2; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04815967
Drug: Phase 3; MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04815967
Drug: Phase 3; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT06081101
Drug: Ketorolac Injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication will be injected into SI joint under ultrasound guidance
Study: NCT05902624
Drug: Hepatitis B Virus Vaccine(HBV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B Virus Vaccine(HBV)
Study: NCT06614153
Drug: HRG2010(II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRG2010(II)
Study: NCT06614153
Drug: Sustained-release Carbidopa/Levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Carbidopa/Levodopa
Study: NCT06685185
Drug: NNC0363-1063
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0363-1063 will be administered subcutaneously.
Study: NCT06685185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT06697535
Drug: Oral Glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
Study: NCT04956809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
Study: NCT00329316
Drug: Crinone Gel 8%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06696755
Drug: Icalcaprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsules
Study: NCT06696755
Drug: Placebo for Icalcaprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsules
Study: NCT04811651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous placebo solution with the same appearance as the treatment group.
Study: NCT05670444
Drug: kelavit
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
Study: NCT05269329
Drug: XC8, film-coated tablets, 20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day (1 tablet twice a day)
Study: NCT05269329
Drug: XC8, film-coated tablets, 40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day (2 tablets twice a day)
Study: NCT05269329
Drug: XC8, film-coated tablets, 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day (4 tablets twice a day)
Study: NCT05269329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, or 4 tablets twice a day